Eledon Pharmaceuticals Inc (ELDN) Stock: What Does the Chart Say Friday?

The market has been high on Eledon Pharmaceuticals Inc (ELDN) stock recently. ELDN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Eledon Pharmaceuticals Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ELDN!

See Full ELDN Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ELDN Stock Today?

Eledon Pharmaceuticals Inc (ELDN) stock is up 10.64% while the S&P 500 is lower by -0.09% as of 10:17 AM on Friday, Mar 22. ELDN has risen $0.20 from the previous closing price of $1.88 on volume of 168,643 shares. Over the past year the S&P 500 is higher by 33.02% while ELDN is lower by -16.80%. ELDN lost -$5.59 per share in the over the last 12 months. To screen for more stocks like Eledon Pharmaceuticals Inc click here.

More About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody. Click Here to get the full Stock Report for Eledon Pharmaceuticals Inc stock.